A previous report elegantly demonstrated that IL-2/JES6-1 immunocomplexes are effective at expanding Foxp3+ T cells in the spleens of mice and when delivered for 1 week prior to the initiation of DSS were able to lessen colitis (22). The gene discussed is FOXP3; the disease is colitis.